Sanofi Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (107)

Latest Posts

About This Stock More About This Stock
E Daily Stock Analysis: Sanofi
Article By: Fredrik Arnold
Sunday, April 4, 2021 7:55 PM EDT
Should Sanofi's stock trade in the range of $40 to $65 this year, its recent $49.67 price might rise by $10.64 to reach $60.00 by April 5, 2022.
In this article: SNY
Read
Sanofi, GSK Delay COVID Vaccine On Low Response In Older Adults
Article By: The Fly
Friday, December 11, 2020 8:25 AM EDT
Sanofi and GlaxoSmithKline announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults.
In this article: GSK, SNY
Read
Sanofi Keeps Sliding, Watch This Trade Level
Article By: Nick Santiago
Wednesday, October 7, 2020 3:00 PM EDT
Currently, the stock is sitting on its important 200-day moving average. This level is still holding up as near term support, but a break below this level will likely spell more problems for the share price.
In this article: SNY
Read
Sanofi To Purchase Immune System-Focused Drugmaker Principia Biopharma For $3.7B
Article By: Benzinga
Monday, August 17, 2020 8:32 AM EDT
Sanofi SA will acquire Principia Biopharma Inc for $3.68 billion in cash, the two companies announced Monday.
In this article: SNY, PRNB Also: GSK, TBIO
Read
Sanofi Acquires Principia Biopharma For $100 Per Share Or $3.68B
Article By: The Fly
Monday, August 17, 2020 5:38 AM EDT
Sanofi and Principia Biopharma entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68B.
In this article: SNY, PRNB
Read

Latest Tweets for $SNY

No tweets yet!

$SNY

There Is Beta In Protalix Stock Due To PRX-102
Paul McGee 8/28/2020 2:44:13 AM

Isn't that made by Sanofi $SNY?

Protalix BioTherapeutics Pipeline Progress
Harry Goldstein 8/10/2020 6:01:37 AM

#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY

Protalix BioTherapeutics Pipeline Progress
Old Time Investor 8/3/2020 2:23:12 PM

My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.

1 to 3 of 3 comments